Clinical trial
Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma
NCT00053781 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00053781 |
|---|---|
| Title | Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma |
| Official title | A Phase II Study Of Perifosine (D-21266) In Previously Untreated Patients With Metastatic Or Recurrent Malignant Melanoma |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | perifosine |
| Enrollment | 18 |
| Start date | Jun 20, 2003 |
| Primary completion | Sep 14, 2004 |
| Completion | Dec 21, 2009 |
| First posted | Feb 6, 2003 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: